Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
April 06 2022 - 6:00AM
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage
biotechnology company developing a new modality of orally delivered
medicines, today announced the appointment of Jose-Carlos
Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of
Directors.
“We are delighted to welcome Jose-Carlos back to our
Board. He is one of the world's preeminent drug discovery and
immunology leaders, and has vast experience across both large
pharmaceutical companies and as well as smaller biotechs,” said
Simba Gill, Ph.D., Chief Executive Officer of Evelo. “Tonya's
experience in government affairs, corporate responsibility, and
communications will be important as we move towards later stage
development and delivering on our vision of providing safe,
effective, oral, and accessible medicines to hundreds of millions
of people around the world.”
About Jose-Carlos Gutiérrez-RamosDr.
Jose-Carlos Gutiérrez-Ramos brings extensive executive experience
in pharmaceutical and biotechnology companies to Evelo. Dr.
Gutiérrez is currently Chief Science Officer at Danaher. Prior to
that role, he was Global Head of Global Drug Discovery at AbbVie.
Dr. Gutierrez-Ramos previously served as Chief Executive Officer
and President of Repertoire Immune Medicine and Chief Executive
Officer and President of Synlogic. Earlier in his career, Dr.
Gutierrez-Ramos held Executive R&D positions at Pfizer,
GlaxoSmithKline, and Takeda. He is currently on the Board of
Directors of Bicycle Therapeutics. Dr. Gutierrez-Ramos received a
B.S. from Universidad Complutense de Madrid and his Ph.D. in
immunochemistry from the Universidad Autonoma de Madrid.
About Tonya WilliamsTonya Williams brings
extensive public and private sector experience to Evelo. Ms.
Williams is currently Head of External Affairs and Corporate
Responsibility at SoftBank Group International, as well as an
adjunct professor at the University of Pennsylvania and
an advisor to Hangar, a public sector investment
firm. Ms. Williams previously worked in the White House as
Director of Legislative Affairs for then-Vice President Joe Biden,
and before that, as Chief of Staff to Congressman G.K. Butterfield
in the U.S. House of Representatives. Earlier in her career, Ms.
Williams served as Vice President for IP Policy at GlaxoSmithKline,
Vice President for Policy & Communications at the W.K. Kellogg
Foundation, and General Counsel to the President Pro Tempore of the
North Carolina Senate. Ms. Williams sits on several non-profit
boards including the Board of Visitors at the MD Anderson Cancer
Center, the Board of Trustees for the Lyndon B. Johnson Foundation,
and the Board of Advisors for the Kenan Institute for Private
Enterprise. Ms. Williams received her J.D. from the University of
North Carolina School of Law and a B.A. in political science from
the University of North Carolina at Chapel Hill.
About Evelo BiosciencesEvelo
Biosciences is a clinical stage biotechnology company
developing orally delivered product candidates that are designed to
act on the small intestinal axis, SINTAX™, with systemic
therapeutic effects. SINTAX plays a central role in governing the
immune, metabolic, and neurological systems. The Company’s first
product candidates are pharmaceutical preparations of single
strains of microbes selected for the potential to offer defined
pharmacological properties. Evelo’s therapies have the potential to
be effective, safe, and affordable medicines to improve the lives
of people with inflammatory diseases.
Evelo currently has three product candidates in development:
EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory
diseases. Evelo is advancing additional product candidates in other
disease areas.
For more information, please visit www.evelobio.com and
engage with Evelo on LinkedIn.
Forward Looking StatementsThis press release
contains forward-looking statements including within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including statements concerning the development of our
product candidates.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: the impact of the COVID-19 pandemic on our operations,
including our preclinical studies and clinical trials, and the
continuity of our business; we have incurred significant losses,
are not currently profitable and may never become profitable; our
need for additional funding; our limited operating history; our
unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development,
including potential delays in regulatory approval; our reliance on
third parties and collaborators to expand our microbial library,
conduct our clinical trials, manufacture our product candidates,
and develop and commercialize our product candidates, if approved;
our lack of experience in manufacturing, selling, marketing, and
distributing our product candidates; failure to compete
successfully against other drug companies; protection of our
proprietary technology and the confidentiality of our trade
secrets; potential lawsuits for, or claims of, infringement of
third-party intellectual property or challenges to the ownership of
our intellectual property; our patents being found invalid or
unenforceable; risks associated with international operations; our
ability to retain key personnel and to manage our growth; the
potential volatility of our common stock; our management and
principal stockholders have the ability to control or significantly
influence our business; costs and resources of operating as a
public company; unfavorable or no analyst research or reports; and
securities class action litigation against us.
These and other important factors discussed under the caption
"Risk Factors" in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2021, and our other reports filed with the
SEC, could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, except as required by law, we disclaim any obligation to do
so, even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
ContactsInvestors:Kendra Sweeney,
239-877-7474ksweeney@evelobio.com
Media:Jessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Apr 2023 to Apr 2024